BD's Q2 Revenues Rise 4 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson said today that its fiscal second-quarter revenues rose nearly 4 percent year over year, beating analyst estimates.

For the quarter ended March 31, 2012, BD posted $1.99 billion in revenues, up from $1.92 billion for the second quarter of 2011, outpacing analysts' consensus estimate of $1.94 billion.

Revenue from the firm's BD Diagnostics segment was up 4 percent to $630 million, compared to $605 million a year ago. Growth was driven primarily by the preanalytical systems unit and women's health and cancer, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.